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Abstract
Purpose: To assess the impact of VA loss on patient reported utilities taking both eyes into account compared to taking
only the better or the worse eye into account.
Methods: In this cross-sectional study 1085 patients and 254 controls rated preferences with the generic health-related (EQ-
5D; n = 868) and vision-specific (Vision and Quality of Life Index (VisQoL); n = 837) multi-attribute utility instruments (MAUIs).
Utilities were calculated for three levels of VA in the better and worse eyes, as well as for 6 different vision states based on
combinations of the better and worse eye VA.
Results: Using the VisQoL, utility scores decreased significantly with deteriorating vision in both the better and worse eyes
when analysed separately. When stratified by the 6 vision states, VisQoL utilities decreased as VA declined in the worse eye
despite stable VA in the better eye. Differences in VisQoL scores were statistically significant for cases where the better eye
had no vision impairment and the worse seeing fellow eye had mild, moderate or severe vision impairment. In contrast, the
EQ-5D failed to capture changes in better or worse eye VA, or any of the six vision states.
Conclusions: Calculating utilities based only on better eye VA or using a generic MAUI is likely to underestimate the impact
of vision impairment, particularly when the better eye has no or little VA loss and the worse eye is moderately to severely
visually impaired. These findings have considerable implications for the assessment of overall visual impairment as well as
economic evaluations within eye health.
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Introduction
Assessing the impact of visual impairment and blindness is met
with the unique challenge that most people have two eyes with
different levels of visual acuity (VA) which contribute to overall
visual function. Therefore, functional impairment which affects
both eyes differently is difficult to quantify overall. Economic
evaluations frequently use utilities based on the better eye or
differentiate between treatment of the worse and/or better eye,[1]
assuming a differential impact on patients’ preferences (utilities)
and quality of life (QoL), resulting in differing cost implications
and cost-benefit ratios.[2] The most commonly used definition of
blindness and visual impairment, published by the World Health
Organization, is based on better eye VA, and the Global Burden
of Disease Study estimates the global impact of visual impairment
based on the better eye only.[3] Often, patients’ preferences are
not directly elicited from the patients but inferred from better eye
VA.[4] The better eye is assumed to predominantly determine
daily visual functioning. However, this disregards the considerable
loss of visual field, depth perception, as well as the anxiety caused
by only having one seeing eye. Even unilateral vision loss has been
shown to reduce independence considerably.[5] Similarly, use of
the better eye only disregards the considerable impact of vision-
restoring treatment in the worse eye, as achieved by for example
cataract surgery or anti-VEGF treatment for neovascular age-
related macular degeneration.[6] Past guidelines, for example,
have recommended that treatment for disorders affecting both
eyes are only made available for the better eye, as demonstrated by
the 2007 draft ‘‘Guidance on the use of LucentisH in neovascular
age-related macular degeneration’’ published by the National
Institute for Health and Clinical Excellence (NICE) in the UK.[7]
To date, very little data on the differential impact of combined VA
for better and worse eyes on utilities are available.[8] In order to
better capture and understand patient preferences and other
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patient reported outcomes, a more detailed assessment of the
association of vision in both eyes and reported preferences is
warranted.
One way of capturing utilities is through multi-attribute utility
instruments (MAUIs) in which values are indirectly elicited
through patient ratings of their health status from a multi-featured
classification system, which allows the comparison of utilities
across different disease states. In Europe, the most commonly used
MAUI is the European Quality of Life Questionnaire (EQ-5D)
which is very well validated and widely available.[9–14] An
alternative to the generic EQ-5D is the Vision and Quality of Life
Index (VisQoL) which is a 6-item vision-specific MAUI developed
and validated specifically for vision-impaired populations.[15]
Time-trade off (TTO), a more direct way to elicit utilities by asking
how much remaining life time a person is willing to trade in return
for perfect health or perfect vision, has been found to be very
sensitive in particular to small changes in vision-related util-
ity.[6,16] However, as it requires a face to face interview, and can
pose a concept difficult to understand, we chose the easier to
administer and comprehend MAUIs. The EQ-5D and the
VisQoL were chosen to capture general and vision specific utility,
respectively.
Based on the argument laid out above, we hypothesize that
assessing vision and visual loss in both eyes allows for a more
robust estimate of utility. Thus we assessed the impact of VA loss
on patient reported utilities taking both eyes into account
compared to taking only the better or the worse eye into account,
using the EQ-5D and the VisQoL MAUIs.
Methods
All patients were recruited from the outpatient clinic at the
department of ophthalmology, University of Munich, Germany,
and the Royal Victorian Eye and Ear Hospital, Australia, between
2009 and 2012. The only exclusion criteria applied was inability to
partake in the interview, based on an inability to speak and/or
read English or German or to comprehend the questionnaire.
Fully sighted persons without any ocular pathology who were
examined as part of a workplace screening intervention were
included as controls, in order to reflect preferences by persons
without any ocular disease or visual impairment, who did not seek
medical care for any visual complaints, as an approximation to the
general population. As anyone attending the respective hospital
during recruitment periods was included, the patient sample is
representative of persons seen at a tertiary eye hospital in
Germany or Australia, respectively. Every participant underwent
vision testing (see below), and a complete ophthalmic examination.
Participants were given the MAUIs for self-completion. Institu-
tional review board approval was obtained from the University of
Munich and the Royal Victorian Eye and Ear Hospital. All
patients gave signed informed consent for study participation and
all studies adhered to the tenets of the Declaration of Helsinki.
Creation of Vision States
Visual acuity was measured using best correction and either
Early Treatment Diabetic Retinopathy Study (ETDRS) or
logarithm of the minimum angle of resolution (LogMAR) retro-
illuminated charts. All VA data were transformed into the
logMAR notation for subsequent analyses. Three categories of
vision impairment (VI) were calculated for the better and worse
eyes, individually (Table 1): (1) No VI (VA $6/12); (2) mild VI
(,6/12–6/18); (3) moderate to severe VI (VA ,6/18). In
addition, with three categories of vision impairment in each eye,
a combination of six different vision states were determined based
on the three categories of VI in each eye (shaded areas in Tables 2
& 3). For example, participants with one good eye (no VI) were
grouped into either of the following three vision states based on the
VA of the other eye: Vision state 1 with good VA in both eyes (VA
$6/12), vision state 2 with good VA in one eye and mild VI (,6/
12–6/18) in the second eye, or vision state 3 with good VA in one
eye and moderate to severe VI in the second eye (VA ,6/18).
Patients with mild VI in their better eye were grouped in either
vision state 4 (mild VI in the fellow eye) or vision state 5 (moderate
– severe VI in the fellow eye). Patients with moderate – severe VI
in both eyes were grouped into vision state 6.
Patient-reported Preferences
Generic health-related patient-reported preferences –
EQ-5D. The EQ-5D is a descriptive system that covers five
dimensions of self-reported health: mobility, self-care, usual
activity, pain/discomfort, and anxiety/depression. [9] Each
dimension has three response categories: no problems, some
problems and extreme problems. For example, a result of 11222
indicates no problems with mobility and self-care but some
problems with the other three dimensions. The 243 health states
defined by the EQ-5D responses were translated into EQ-5D
index utilities using available values sets that have been derived
from large population-based surveys.[17,18] The scale of the
utility index ranges between 0.0 and 1.0, where 0.0 represents
death and 1.0 represents full health. States that are considered
‘worse than death’ are represented by negative utility values. Since
no value set currently exists for the Australian population, or a
mixed Australian and German sample we used the New Zealand
value set [18] (VAS valuation method) as more Australian
participants rated the EQ-5D.
Vision-related patient-reported preferences – the
VisQoL. The VisQoL is a descriptive system that covers six
dimensions of self-reported vision-related quality of life (VRQoL):
physical well-being, independence, social well-being, self-actualisa-
tion, and planning and organisation. [15,19] Each question is
preceded by ‘‘Does my vision…’’ and each dimension has between
five and six response categories, ranging from, for example, ‘no
effect’ to ‘unable to do’. Two dimensions also have a ‘non-
applicable’ option. The health states defined by the VisQoL
responses were translated into VisQoL utilities using an available
value set derived from surveys using the TTO method.[15] The
value set was generated as part of the instrument validation, using
a range of health states and a visually impaired as well as a visually
unimpaired sample.[19] Item utilities were combined using a
multiplicative model and the scale of the utility index ranges from
0–1, where 0.0 represents the worst imaginable vision-related
health state, i.e. blindness, and 1.0 represents the best imaginable
vision-related health state, i.e. perfect vision. Health states rated
worse than blindness are represented by negative utility values.
Statistical Analyses
The SPSS statistical software (Version 19.0, SPSS Science,
Chicago, IL) was used to analyze the data. Participants with
missing visual acuity data were excluded from all analyses. Other
missing data were not inferred, but patients excluded from the
respective analyses. Descriptive statistical analyses were performed
to characterize the participants and their utilities. The correlation
between utility measures and participants’ characteristics were
explored using Spearman’s rank correlation. Utility measures were
not compared directly. For each utility instrument (VisQoL and
EQ-5D), utilities per vision state and across better and worse eye
VI categories were compared using using post-hoc Bonferroni
testing following analysis of covariance, controlling for age and
Impact of Both Eye Visual Acuity on Utilities
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gender (ANCOVA). All tests were considered to be statistically
significant at a level of p,0.05 and corrections were made for
multiple testing.
Results
The overall sample consisted of 1085 patients and 254 fully
sighted controls without any ocular pathology, of which 543 were
interviewed in Australia and 796 in Germany. Mean 6 standard
deviation (SD) age was 62615 years, with equal gender
proportions (50% female, Table 1). The mean (6SD) VA in
the better eye was 0.2460.32 (LogMAR). A total of 837
respondents rated the VisQoL, and 868 rated the EQ-5D. Of
these, 384 rated both instruments. Overall, the majority of patients
had diabetic eye diseases (diabetic retinopathy and/or diabetic
macular edema; n= 730, 67%), followed by age-related macular
degeneration (n= 243, 23%), and other ocular diseases such as
cataract and glaucoma (n = 109, 10%). The German and the
Australian patient samples did not differ except for the proportion
of persons with diabetic eye disease which was larger in the
Australian sample (p,0.05). Controls did not differ in gender
proportions from patients, but were younger (4669 versus 66613
years; p,0.001) and had a better VA (0.0360.09 versus
0.2860.33; p,0.001).
All utility scores correlated with age (all p,0.03), but only
VisQoL utilities were correlated with VA for better and worse eyes
(r =20.451 and r =20.481, respectively, both p,0.001).
Using the VisQoL, utility scores decreased significantly with
deteriorating vision in both the better and worse eyes, separately
(all p,0.001, Figure 1, Table 2). Considering the different vision
states based on both eye VA, reported VisQoL utilities decreased
with deteriorating vision in the worse eye despite no change in the
better eye (rows in shaded area in Table 2). This was statistically
significant for mild (,6/12–6/18, p#0.001) or moderate to severe
(,6/18, p#0.001) VI in the worse seeing fellow eye despite stable
and very good vision in the better seeing eye (no VI .6/18,
Table 1. Characteristics of the sample.
All n=1339 EQ-5D n=868 VisQoL n=837
n (%) or mean 6 SD
Country Germany 796(60%) 387(45%) 606(72%)
Australia 543(40%) 481(55%) 231(28%)
Age* 62.1615.0 65.7612.0 60.2615.9
Gender* Male 631(46%) 471(54%) 353(42%)
Female 680(50%) 372(43%) 459(55%)
Participant Patient 1085(80%) 868(100%) 583(70%)
Control 254(20%) 0 254(30%)
Ocular condition* (patients only) AMD 243(23%) 157(18%) 170(29%)
DR/DME 730(67%) 620(71%) 308(53%)
Other 109 (10%) 88(10%) 102(18%)
Better eye VA (LogMAR) .246.32 .226.28 .236.33
Better eye VA categories 6/12 or better no VI 893 (66%) 558(64%) 577(69%)
,6/12–6/18 mild VI 209(15%) 154(18%) 102(12%)
,6/18 moderate - severe VI 208(15%) 137(16%) 128(15%)
AMD= age-related macular degeneration; DR= diabetic retinopathy; DME=diabetic macular oedema; VA = visual acuity; VisQoL = Vision and Quality of Life Index; EQ-
5D= Euro Quality of Life Questionnaire; LogMAR= logarithm of the minimum angle of resolution.*data incomplete.
doi:10.1371/journal.pone.0081042.t001
Table 2. VisQoL utility scores by better or worse eye category and per vision state (by VA category).
VA categories worse eye
Better eye VA
categories Better eye only 6/12 or better ,6/12–6/18 ,6/18
No VI Mild VI Moderate – Severe VI
6/12 or better No VI .926.13* n = 577 .956.10 n=371 .906.16* n=111 .866.17* n=95













VA= visual acuity, VisQoL = Vision and Quality of Life Index, *indicates significant difference (p#0.001) between categories using post-hoc Bonferroni testing following
ANCOVA. Bolded data correspond to the 6 vision states relating to combined categories of VI in the better and worse seeing eyes.
doi:10.1371/journal.pone.0081042.t002
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Figure 1, Table 2). In contrast, EQ-5D utilities did not differ
according to better eye VA, worse eye VA or by vision states
considering both eyes (Figure 1, Table 3).
Discussion
Using the VisQoL, the use of better eye VA only, or VA of one
eye only, may be suboptimal when determining utilities, partic-
ularly in cases with good better eye function and moderate to
severe visual impairment in the fellow eye. Our data show that
determination of vision-related utility values should be guided by
VA in both eyes with specific attention given to the worse eye in
cases with good seeing better eyes. This finding has considerable
implications for defining visual impairment, burden of disease and
economic evaluations within eye health as well as treatment
decisions, as the conventional maxim ‘‘still got one good eye’’,
referring to basing treatment or other decisions on better eye VA,
is unlikely to reflect patients’ preferences. We found that the EQ-
5D generic MAUI was completely unresponsive to different VA
levels in a large sample of patients as has been suggested by work
from this group previously.[20] Conversely, the VisQoL - a vision-
related MAUI – was better able to record utilities associated with
vision impairment.
Contrary to the assumption that the better eye solely or mostly
determines vision-related activity limitation, quality of life and
utilities, treatment of the better and worse eye confers a patient
reported benefit. In a previous study we demonstrated that
improvements in utilities did not depend on whether the better or
worse eye was treated in patients with neovascular AMD.[8] In
large, pivotal phase III studies of treatment for neovascular AMD,
the observed increase in visual functioning as measured with a
vision-specific patient reported outcome measure, the National
Eye institute Visual Functioning Questionnaire 25 items (NEI-
VFQ-25), has been similar regardless of whether the better or
worse eye was treated.[21] Similarly, surgical interventions for
macular holes have been associated with an increase in VRQoL
without a corresponding change in VA in the treated eye which, in
most cases, remained the worse eye even after a successful
intervention.[22] The findings from the current study of an
additional impact of worse eye VA on reported utilities combined
with the above evidence that improvements in utilities and
VRQoL are often irrespective of better or worse eye treatment,
suggest that resource allocation and treatment decisions should not
be based on better eye VA only. Nor should treatments be made
available for the better eye only in bilaterally affected cases. On the
contrary, evidence strongly suggests that patients should have
access to treatment and care the moment visual function in either
Table 3. EQ-5D (NZ VAS weighting) utility scores by better or worse eye category and per vision state (by VA category).
VA categories worse eye
Better eye VA
categories Better eye only 6/12 or better ,6/12–6/18 ,6/18
No VI Mild VI Moderate – Severe VI
6/12 or better No VI .716.23 n = 558 .706.22 n=247 .716.24 n=170 .736.23 n=141
,6/12–6/18 Mild VI .696.23 n = 154 .686.23 n=47 .706.24 n=107
,6/18 Moderate –
Severe VI
.676.23 n = 137 .676.23 n=137
Worse eye only .706.22 n = 247 .706.24 n = 217 .706.23 n = 385
VA= visual acuity, EQ-5D= Euro Quality of Life Questionnaire, VAS= visual analogue scale, NZ =New Zealand value set. Bolded data correspond to the 6 vision states
relating to combined categories of VI in the better and worse seeing eyes.
doi:10.1371/journal.pone.0081042.t003
Figure 1. Utility across all six vision states (VS), for the VisQoL and the EQ-5D utility instruments, demonstrating a reduction of
visual acuity with worsening vision states for the VisQoL but not the EQ-5D.
doi:10.1371/journal.pone.0081042.g001
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eye is affected. Studies based on the better eye VA only are likely
to under-estimate the impact of visual impairment and its overall
burden. For example, the burden of visual impairment estimated
by the Global Burden of Disease study [3] is likely to be higher as a
large proportion of patients with no VI in their better eye but even
only mild VI in their fellow worse seeing eye will be impacted and
should be considered to contribute to the overall burden, as shown
in our study. However, these cases are disregarded in the currently
employed methodology.
Utility values used for economic evaluation in ophthalmology
are often deducted using approximations from clinical data (e.g.
VA of the better eye) rather than from directly collected
utilities.[10,13,23,24] Utilities directly derived from patients, and
based on VA in both eyes, are very likely to differ from utility
values inferred from VA of the better eye only. Collecting utilities
directly from patients is more resource intensive than inferring
them from VA, but likely to yield more differentiated and
authentic health or vision states as well as corresponding utilities.
One possible compromise could be to use a table similar to this
study (e.g. Table 2), which reflects the VA of both eyes in
combination. However, further research in another sample with a
greater differentiation of ocular conditions as well as larger
numbers is required to validate this methodology. This would
allow to stratify VA into finer categories as well. Given these issues,
it remains a challenge to find the optimal method of accurately
assessing utilities related to vision impairment and treatment in
ophthalmology which is specific yet comparable across different
diseases and impairments.
Strengths of our study include the use of a standard generic
MAUI and a vision-specific MAUI in a very large sample of more
than 1000 patients recruited at two centres who underwent a
complete ophthalmic examination and standardized vision assess-
ment. The main limitation of our study is the small sample size of
some of the six combined vision states, particularly those
comprising poor VA in both eyes, which may have diminished
our ability to reveal significant associations. As this was an
exploratory study, we did not conduct formal sample size
calculations to inform recruitment. Collating data collected in
Australia and Germany may have limitations due to cross-cultural
differences. Distance VA may not be the most appropriate clinical
measure to represent functional vision, with a number of studies
suggesting that contrast sensitivity may be more highly associated
with visual functioning and utilities.[23,25,26] However, as best
corrected VA is the most widely used and standardized measure in
daily clinical routine this ultimately enhances the generalisability
of our findings. Similarly, the somewhat crude categorization into
three different levels of vision impairment may lead to a loss of
information. Future studies should aim to recruit more partici-
pants which would then allow for a finer categorization of vision.
In conclusion, calculating utilities based only on better eye VA is
likely to underestimate the impact of vision impairment, in
particular when the better eye functions well and the other (worse)
eye is moderately or severely visually impaired. These findings
have considerable implications for defining visual impairment, for
economic evaluations within eye health as well as for treatment
decisions, as the conventional maxim ‘‘still got one good eye’’ is
likely to not reflect patients’ preferences and underestimate the
impact of poor vision in either eye.
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